Granules India Past Earnings Performance
Past criteria checks 2/6
Granules India has been growing earnings at an average annual rate of 10.4%, while the Pharmaceuticals industry saw earnings growing at 14.2% annually. Revenues have been growing at an average rate of 15.5% per year. Granules India's return on equity is 13.3%, and it has net margins of 8.7%.
Key information
10.4%
Earnings growth rate
11.3%
EPS growth rate
| Pharmaceuticals Industry Growth | 17.5% |
| Revenue growth rate | 15.5% |
| Return on equity | 13.3% |
| Net Margin | 8.7% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Granules India makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 45,261 | 3,953 | 5,877 | 0 |
| 30 Sep 23 | 45,166 | 3,939 | 5,499 | 0 |
| 30 Jun 23 | 44,779 | 4,369 | 5,187 | 0 |
| 31 Mar 23 | 45,119 | 5,166 | 4,872 | 0 |
| 31 Dec 22 | 43,464 | 5,080 | 4,781 | 0 |
| 30 Sep 22 | 41,970 | 4,845 | 4,643 | 0 |
| 30 Jun 22 | 39,346 | 4,201 | 4,391 | 0 |
| 31 Mar 22 | 37,649 | 4,128 | 4,123 | 0 |
| 31 Dec 21 | 35,343 | 4,293 | 4,113 | 0 |
| 30 Sep 21 | 33,820 | 4,753 | 4,069 | 0 |
| 30 Jun 21 | 33,518 | 5,582 | 4,189 | 0 |
| 31 Mar 21 | 32,375 | 5,495 | 4,248 | 0 |
| 31 Dec 20 | 30,381 | 5,142 | 3,412 | 0 |
| 30 Sep 20 | 28,976 | 4,314 | 3,228 | 0 |
| 30 Jun 20 | 27,390 | 3,636 | 2,857 | 0 |
| 31 Mar 20 | 25,986 | 3,354 | 3,217 | 0 |
| 31 Dec 19 | 26,121 | 3,071 | 2,537 | 0 |
| 30 Sep 19 | 25,399 | 3,034 | 2,425 | 0 |
| 30 Jun 19 | 24,212 | 2,679 | 2,166 | 0 |
| 31 Mar 19 | 22,792 | 2,364 | 2,269 | 0 |
| 31 Dec 18 | 21,697 | 1,928 | 2,158 | 0 |
| 30 Sep 18 | 19,487 | 1,675 | 2,037 | 0 |
| 30 Jun 18 | 17,603 | 1,476 | 1,764 | 0 |
| 31 Mar 18 | 16,846 | 1,326 | 1,801 | 0 |
| 31 Dec 17 | 15,361 | 1,578 | 1,692 | 0 |
| 30 Sep 17 | 14,785 | 1,619 | 1,638 | 0 |
| 30 Jun 17 | 14,456 | 1,624 | 1,453 | 0 |
| 31 Mar 17 | 14,106 | 1,645 | 1,504 | 0 |
| 31 Dec 16 | 14,971 | 1,473 | 1,614 | 85 |
| 30 Sep 16 | 14,626 | 1,374 | 1,479 | 63 |
| 30 Jun 16 | 14,524 | 1,289 | 1,423 | 28 |
| 31 Mar 16 | 13,572 | 1,230 | 1,283 | 0 |
| 31 Dec 15 | 14,147 | 1,077 | 2,377 | 187 |
| 30 Sep 15 | 13,895 | 1,041 | 2,366 | 160 |
| 30 Jun 15 | 13,307 | 952 | 2,317 | 134 |
| 31 Mar 15 | 12,937 | 909 | 1,155 | 0 |
| 31 Dec 14 | 12,573 | 921 | 2,261 | 51 |
| 30 Sep 14 | 12,217 | 904 | 2,188 | 57 |
| 30 Jun 14 | 11,786 | 834 | 1,472 | 64 |
| 31 Mar 14 | 10,973 | 752 | 2,051 | 94 |
| 31 Dec 13 | 9,837 | 640 | 1,656 | 49 |
| 30 Sep 13 | 8,948 | 480 | 1,569 | 51 |
| 30 Jun 13 | 8,034 | 410 | 1,105 | 48 |
Quality Earnings: 532482 has high quality earnings.
Growing Profit Margin: 532482's current net profit margins (8.7%) are lower than last year (11.7%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 532482's earnings have grown by 10.4% per year over the past 5 years.
Accelerating Growth: 532482's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 532482 had negative earnings growth (-22.2%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (23.1%).
Return on Equity
High ROE: 532482's Return on Equity (13.3%) is considered low.